Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Merck & Company (MRK)

Merck & Company (MRK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Merck & Company 126 East Lincoln Avenue Rahway NJ 07065 USA

www.merck.com Employees: 75,000 P: 908-740-4000

Sector:

Medical

Description:

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.

Key Statistics

Overview:

Market Capitalization, $K 301,962,912
Enterprise Value, $K 323,182,912
Shares Outstanding, K 2,482,023
Float, K 2,478,796
% Float 99.87%
Short Interest, K 28,729
Short Float 1.16%
Days to Cover 2.38
Short Volume Ratio 0.67
% of Insider Shareholders 0.13%
% of Institutional Shareholders 76.07%

Financials:

Annual Sales, $ 65,011 M
Annual Net Income, $ 18,254 M
Last Quarter Sales, $ 16,400 M
Last Quarter Net Income, $ 2,963 M
EBIT, $ 22,108 M
EBITDA, $ 26,607 M

Growth:

1-Year Return 42.36%
3-Year Return 10.71%
5-Year Return 67.53%
5-Year Revenue Growth 35.46%
5-Year Earnings Growth 51.18%
5-Year Dividend Growth 32.26%

Per-Share Information:

Most Recent Earnings 2.04 on 02/03/26
Next Earnings Date 04/23/26
Earnings Per Share ttm 8.97
EPS Growth vs. Prev Qtr -20.93%
EPS Growth vs. Prev Year 18.60%
Annual Dividend & Yield (Paid) 3.28 (2.70%)
Annual Dividend & Yield (Fwd) 3.40 (2.80%)
Most Recent Dividend 0.850 on 12/15/25
Next Ex-Dividends Date 03/16/26
Dividend Payable Date 04/07/26
Dividend Payout Ratio 36.47%
Most Recent Split 2-1 on 02/17/99

MRK Ratios

Ratio
Price/Earnings ttm 13.55
Price/Earnings forward 23.65
Price/Earnings to Growth 2.27
Return-on-Equity % 45.22%
Return-on-Assets % 18.65%
Profit Margin % 28.08%
Debt/Equity 0.77
Price/Sales 4.64
Price/Cash Flow 12.84
Price/Book 5.85
Book Value/Share 20.78
Interest Coverage 2.96
60-Month Beta 0.28

MRK Dividends

Date Value
12/15/25 $0.8500
09/15/25 $0.8100
06/16/25 $0.8100
06/15/25 $0.8100
03/17/25 $0.8100
12/16/24 $0.8100
09/16/24 $0.7700
06/17/24 $0.7700
03/14/24 $0.7700
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar